CheckMate 214
CheckMate 214 is the trial that brought dual immunotherapy to kidney cancer, with a survival advantage still visible eight years later and a fifth of patients in long-term remission.
Intermediate/poor-risk: OS HR 0.69 at 8 years; ITT OS HR 0.72; complete response ~12% with many durable off treatment. Favourable-risk patients did not gain OS. FDA approval April 2018. The comparator for every later first-line RCC trial and the backbone of COSMIC-313 and PDIGREE.
- The treated group had about 31 percent lower chance of the event at any given time (hazard ratio 0.69).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- The treated group had about 28 percent lower chance of the event at any given time (hazard ratio 0.72).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Untreated advanced clear-cell RCC: nivolumab + ipilimumab vs sunitinib. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,096 participants enrolled.
Numbers not yet public.
SourceNumbers not yet public.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival, intermediate/poor risk (8-year follow-up)primary | Nivolumab + ipilimumab | 425 | — | 0.69 (0.59–0.81) | — | link |
| Sunitinib | 422 | — | ||||
| Overall survival, ITT (8-year follow-up) | Nivolumab + ipilimumab | 550 | — | 0.72 (0.62–0.83) | — | — |
| Sunitinib | 546 | — |
Pages like this
not linked directly; found by shared links- PairingIMDC risk → first-line regimen choice (RCC)
Shares IMDC risk groups (favourable / intermediate / poor), Sarcomatoid differentiation (RCC), Ipilimumab, Nivolumab.
- TrialCLEAR (KEYNOTE-581)
Shares IMDC risk groups (favourable / intermediate / poor), Sunitinib, Renal cell carcinoma.
- TrialKEYNOTE-426
Shares IMDC risk groups (favourable / intermediate / poor), Sunitinib, Renal cell carcinoma.
- TrialCOSMIC-313
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialCheckMate 9ER
Shares Sunitinib, Nivolumab, Renal cell carcinoma.
- TrialCheckMate 648
Shares Ipilimumab, Nivolumab.
- TrialCheckMate 9DW
Shares Ipilimumab, Nivolumab.
- PersonJames Larkin
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.